Crossmark

CD36 – a plausible modifier of disease phenotype in familial adenomatous polyposis

Crossref DOI link: https://doi.org/10.1186/s13053-018-0096-y

Published Online: 2018-07-28

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Holmes, Merran

Connor, Toni

Oldmeadow, Christopher

Pockney, Peter G.

Scott, Rodney J.

Talseth-Palmer, Bente A. https://orcid.org/0000-0003-0286-7161
Funding

Funding for this research was provided by:

the Liaison Committee between the Central Norway Regional Health Authority (RHA) and the Norwegian University of Science and Technology (NTNU)

Møre and Romsdal Hospital Trust

Cancer Institute NSW
License Information

Text and Data Mining valid from 2018-07-28
More Information

Article History

Received: 1 March 2018

Accepted: 19 July 2018

First Online: 28 July 2018

Ethics approval and consent to participate

: All patients consented for the use of their de-identified DNA to be used in future research into their condition. The study was approved by the Hunter New England Human Research Ethics Committee and Human Research Ethics Committee of the University of Newcastle, Newcastle, Australia.

: Not applicable.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.